$PULM
Pulmatrix, Inc. Stock $pulm

$pulm Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000119312518326795 Filed on November 14, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$153.0K	$0.00	$335.0K
YoY Change		-100.0%	449.18%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.590M	$1.770M	$2.020M
YoY Change	-13.59%	-12.38%	30.32%
% of Gross Profit
Research & Development	$3.221M	$3.056M	$2.618M
YoY Change	24.36%	16.73%	73.72%
% of Gross Profit
Depreciation & Amortization	$50.00K	$60.00K	$60.00K
YoY Change	-16.67%	0.0%	0.0%
% of Gross Profit
Operating Expenses	$5.267M	$4.825M	$4.639M
YoY Change	18.89%	4.01%	51.75%
Operating Profit	-$5.114M	-$4.825M	-$4.304M
YoY Change		12.11%	43.66%
Interest Expense	$106.0K	$0.00	$153.0K
YoY Change	-206.0%	-100.0%	-32.0%
% of Operating Profit
Other Income/Expense, Net	-$1.000K	$1.000K	$5.000K
YoY Change		-80.0%	-92.19%
Pretax Income	-$4.340M	-$4.820M	-$4.450M
YoY Change	-3.98%	8.31%	40.82%
Income Tax
% Of Pretax Income
Net Earnings	-$5.221M	-$4.816M	-$4.452M
YoY Change	15.51%	8.18%	41.02%
Net Earnings / Revenue	-3412.42%		-1328.96%
Basic Earnings Per Share
Diluted Earnings Per Share	-$869.7K	-$1.028M	-$2.203M
COMMON SHARES
Basic Shares Outstanding	46.93M shares	46.93M shares	20.12M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.560M	$3.810M	$6.360M
YoY Change	-27.89%	-40.09%	-13.0%
Cash & Equivalents	$2.563M	$3.806M	$6.360M
Short-Term Investments
Other Short-Term Assets	$720.0K	$910.0K	$890.0K
YoY Change	2.86%	2.25%	332.04%
Inventory
Prepaid Expenses
Receivables			$305.0K
Other Receivables			$0.00
Total Short-Term Assets	$3.280M	$4.720M	$7.550M
YoY Change	-22.75%	-37.48%	-9.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$394.0K	$447.0K	$657.0K
YoY Change	-35.83%	-31.96%	-34.23%
Goodwill	$10.85M	$10.91M	$10.91M
YoY Change	-0.63%	0.0%	-31.54%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$11.44M	$11.57M	$11.78M
YoY Change	-2.46%	-1.78%	-31.32%
TOTAL ASSETS
Total Short-Term Assets	$3.280M	$4.720M	$7.550M
Total Long-Term Assets	$11.44M	$11.57M	$11.78M
Total Assets	$14.72M	$16.29M	$19.33M
YoY Change	-7.85%	-15.73%	-24.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.183M	$1.367M	$1.027M
YoY Change	158.86%	33.11%	156.11%
Accrued Expenses	$1.696M	$2.284M	$1.587M
YoY Change	-21.55%	43.92%	33.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00		$3.896M
YoY Change	-100.0%		55.16%
Total Short-Term Liabilities	$2.879M	$3.651M	$6.510M
YoY Change	-50.7%	-43.92%	58.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$0.00		$40.00K
YoY Change			300.0%
Total Long-Term Liabilities	$0.00	$0.00	$40.00K
YoY Change		-100.0%	-98.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.879M	$3.651M	$6.510M
Total Long-Term Liabilities	$0.00	$0.00	$40.00K
Total Liabilities	$2.879M	$3.650M	$6.545M
YoY Change	-50.71%	-44.23%	-18.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$194.6M	-$190.2M	-$169.5M
YoY Change	11.82%	12.24%	15.99%
Common Stock	$206.4M	$202.9M	$182.3M
YoY Change	12.09%	11.3%	11.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.84M	$12.63M	$12.78M
YoY Change
Total Liabilities & Shareholders Equity	$14.72M	$16.29M	$19.33M
YoY Change	-7.85%	-15.73%	-24.16%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$5.221M	-$4.816M	-$4.452M
YoY Change	15.51%	8.18%	41.02%
Depreciation, Depletion And Amortization	$50.00K	$60.00K	$60.00K
YoY Change	-16.67%	0.0%	0.0%
Cash From Operating Activities	-$4.160M	-$4.520M	-$4.620M
YoY Change	29.6%	-2.16%	65.0%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$10.00K	-$30.00K
YoY Change	-66.67%	-66.67%	-88.89%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$10.00K	-$10.00K	-$30.00K
YoY Change	-66.67%	-66.67%	-88.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.930M	-10.00K	20.00K
YoY Change	565.91%	-150.0%	-104.88%
NET CHANGE
Cash From Operating Activities	-4.160M	-4.520M	-4.620M
Cash From Investing Activities	-10.00K	-10.00K	-30.00K
Cash From Financing Activities	2.930M	-10.00K	20.00K
Net Change In Cash	-1.240M	-4.540M	-4.630M
YoY Change	-55.71%	-1.94%	33.05%
FREE CASH FLOW
Cash From Operating Activities	-$4.160M	-$4.520M	-$4.620M
Capital Expenditures	-$10.00K	-$10.00K	-$30.00K
Free Cash Flow	-$4.150M	-$4.510M	-$4.590M
YoY Change	30.5%	-1.74%	81.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	46927221	shares
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6360000
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2284000
CY2018Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	71000
CY2018Q3	us-gaap	Assets Current AssetsCurrent	4720000
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	202856000
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1367000
CY2018Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1229000
CY2018Q3	us-gaap	Assets Assets	16285000
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3806000
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3806000
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46927221	shares
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46927221	shares
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	5000
CY2018Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0
CY2018Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0
CY2018Q3	us-gaap	Deferred Rent Credit DeferredRentCredit	67000
CY2018Q3	us-gaap	Deferred Costs Current DeferredCostsCurrent	449000
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4218000
CY2018Q3	us-gaap	Goodwill Goodwill	10914000
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3651000
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16285000
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12000
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	698000
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1538000
CY2018Q3	pulm	Accrued Legal And Patent Current AccruedLegalAndPatentCurrent	93000
CY2018Q3	pulm	Accrued Clinical And Consulting Current AccruedClinicalAndConsultingCurrent	812000
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	184137000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	457000
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	676000
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	164000
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Prepaid Insurance PrepaidInsurance	291000
CY2018Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	131000
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	447000
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	914000
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	204000
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-190227000
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.34
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10247905	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4502002	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.89
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10413544	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.32
CY2018Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	0
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	12634000
CY2018Q3	pulm	Prepaid Clinical Trials PrepaidClinicalTrials	43000
CY2018Q3	pulm	Debt Instrument Accretion Of Debt Discount DebtInstrumentAccretionOfDebtDiscount	35000
CY2018Q3	pulm	Working Capital Deficit WorkingCapitalDeficit	1069000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4182000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2162000
CY2017Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	57000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	4246000
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1113000
CY2017Q4	us-gaap	Assets Assets	15978000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3550000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3550000
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21047498	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21047498	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	2000
CY2017Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3221000
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	35000
CY2017Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	68000
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1000
CY2017Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	27000
CY2017Q4	us-gaap	Goodwill Goodwill	10914000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5841000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15978000
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3221000
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	70000
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Prepaid Insurance PrepaidInsurance	204000
CY2017Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	44000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	614000
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	696000
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	204000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-174002000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3695634	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.69
CY2017Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	3000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	10137000
CY2017Q4	pulm	Accrued Legal And Patent Current AccruedLegalAndPatentCurrent	61000
CY2017Q4	pulm	Accrued Clinical And Consulting Current AccruedClinicalAndConsultingCurrent	568000
CY2017Q4	pulm	Accrued End Of Term Fee AccruedEndOfTermFee	225000
CY2017Q4	pulm	Prepaid Clinical Trials PrepaidClinicalTrials	421000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2178000
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	9000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	186000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.72
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5727000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	259000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	308000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	305000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	198000
	us-gaap	Interest Expense InterestExpense	512000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13479000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11265000
	us-gaap	Net Income Loss NetIncomeLoss	-13532000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3000
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	21000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	26000
	us-gaap	Operating Expenses OperatingExpenses	13381000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13046000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	304000
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-1995000
	us-gaap	Profit Loss ProfitLoss	-13532000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7654000
	us-gaap	Revenues Revenues	335000
	us-gaap	Share Based Compensation ShareBasedCompensation	2077000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	2077000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18738118	shares
	pulm	Non Cash Interest Expenses NonCashInterestExpenses	135000
	pulm	Noncash Rent Expense NoncashRentExpense	16000
	pulm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	15170000
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3000
	us-gaap	Basis Of Accounting BasisOfAccounting	<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>2. Basis of Presentation</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a going concern basis in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by Regulation <font style="white-space:nowrap">S-X,</font> Rule <font style="white-space:nowrap">10-01.</font> Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three months and nine months ended September 30, 2018, are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2018. For further information, refer to the financial statements and footnotes included in the Company’s annual financial statements for the fiscal year ended December 31, 2017, which are included in the Company’s annual report on Form <font style="white-space:nowrap">10-K</font> filed with the SEC on March 13, 2018.</p> </div>
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	256000
	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	3259000
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	3000
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	175000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5930000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	910000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	219000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1000
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Type DocumentType	10-Q
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
	dei	Entity Central Index Key EntityCentralIndexKey	0001574235
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
	dei	Entity Registrant Name EntityRegistrantName	Pulmatrix, Inc.
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	347000
	us-gaap	Interest Expense InterestExpense	186000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12860000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12596000
	us-gaap	Net Income Loss NetIncomeLoss	-16225000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	28000
	us-gaap	Operating Expenses OperatingExpenses	16220000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16067000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8000
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-3259000
	us-gaap	Profit Loss ProfitLoss	-16225000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10290000
	us-gaap	Revenues Revenues	153000
	us-gaap	Share Based Compensation ShareBasedCompensation	2358000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	2358000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	23090	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y11M8D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6741000	shares
	dei	Trading Symbol TradingSymbol	PULM
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.47
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.28
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y8M26D
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5000
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	4639000
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4304000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payments, estimating fair value of equity instruments recorded as derivative liabilities, estimating the useful lives of depreciable and amortizable assets, valuation allowance against deferred tax assets, goodwill impairment, and estimating the fair value of long-lived assets to assess whether impairment charges may apply.</p> </div>
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38393842	shares
	pulm	Non Cash Interest Expenses NonCashInterestExpenses	55000
	pulm	Fair Value Adjustment On Derivative Liability FairValueAdjustmentOnDerivativeLiability	-1000
	pulm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	16364000
	pulm	Fair Value Of Warrant Derivative Liabilities At Issuance Recorded As Debt Discount FairValueOfWarrantDerivativeLiabilitiesAtIssuanceRecordedAsDebtDiscount	0
	pulm	End Of Term Payments EndOfTermPayments	-245000
CY2015	pulm	Fair Value Of Warrant Derivative Liabilities At Issuance Recorded As Debt Discount FairValueOfWarrantDerivativeLiabilitiesAtIssuanceRecordedAsDebtDiscount	11000
CY2017	pulm	Fair Value Of Warrant Derivative Liabilities At Issuance Recorded As Debt Discount FairValueOfWarrantDerivativeLiabilitiesAtIssuanceRecordedAsDebtDiscount	1000
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2021000
CY2017Q3	us-gaap	Interest Expense InterestExpense	153000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-4452000
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2618000
CY2017Q3	us-gaap	Revenues Revenues	335000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-4816000
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	740000
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20200893	shares
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1769000
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9000
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	4825000
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4825000
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3056000
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	660000
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	46927221	shares

Files In Submission

Name	View Source	Status
0001193125-18-326795-index-headers.html	Edgar Link	pending
0001193125-18-326795-index.html	Edgar Link	pending
0001193125-18-326795.txt	Edgar Link	pending
0001193125-18-326795-xbrl.zip	Edgar Link	pending
d637169d10q.htm	Edgar Link	pending
d637169dex311.htm	Edgar Link	pending
d637169dex312.htm	Edgar Link	pending
d637169dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pulm-20180930.xml	Edgar Link	completed
pulm-20180930.xsd	Edgar Link	pending
pulm-20180930_cal.xml	Edgar Link	unprocessable
pulm-20180930_def.xml	Edgar Link	unprocessable
pulm-20180930_lab.xml	Edgar Link	unprocessable
pulm-20180930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PULM
Pulmatrix, Inc. Stock $pulm

2018 Q4 Form 10-Q Financial Statement

#000119312518326795 Filed on November 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM Pulmatrix, Inc. Stock $pulm

2018 Q4 Form 10-Q Financial Statement

#000119312518326795 Filed on November 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM
Pulmatrix, Inc. Stock $pulm